388 related articles for article (PubMed ID: 23574573)
21. Medical therapy for acromegaly.
Newman CB
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin analogs in medical treatment of acromegaly.
Racine MS; Barkan AL
Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.
Garrido MJ; Cendrós JM; Ramis J; Peraire C; Obach R; Trocóniz IF
J Clin Pharmacol; 2012 Apr; 52(4):487-98. PubMed ID: 21551318
[TBL] [Abstract][Full Text] [Related]
25. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
26. Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment.
Matta M; Bongard V; Grunenwald S; Maiza JC; Bennet A; Caron P
Eur J Endocrinol; 2011 Jun; 164(6):885-9. PubMed ID: 21471168
[TBL] [Abstract][Full Text] [Related]
27. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
28. [Possibilities of medical treatment in acromegaly].
Cáp J; Nemecek S; Rezácová M; Cerman J
Cas Lek Cesk; 2005; 144 Suppl 3():33-4, 36-7. PubMed ID: 16335261
[TBL] [Abstract][Full Text] [Related]
29. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
30. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
31. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
32. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
33. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy).
Colao A; Vandeva S; Pivonello R; Grasso LF; Nachev E; Auriemma RS; Kalinov K; Zacharieva S
Eur J Endocrinol; 2014 Aug; 171(2):263-73. PubMed ID: 24878680
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Ramírez C; Vargas G; González B; Grossman A; Rábago J; Sosa E; Espinosa-de-Los-Monteros AL; Mercado M
Eur J Endocrinol; 2012 Jan; 166(1):21-6. PubMed ID: 21993154
[TBL] [Abstract][Full Text] [Related]
35. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Moyes VJ; Metcalfe KA; Drake WM
Eur J Endocrinol; 2008 Nov; 159(5):541-5. PubMed ID: 18708434
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
38. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
Petersenn S; Houchard A; Sert C; Caron PJ;
Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
